Fallopian Tube Adenocarcinoma, Ovarian Adenocarcinoma, Primary Peritoneal Carcinoma
Conditions
Brief summary
HCIP has shown efficacy in treatment of peritoneal carcinosis from colorectal background. Few studies have been published on the use of HCIP in peritoneal carcinosis from ovarian background but most of them were non-randomized phase II studies on a small population using different type of drugs and dosage. before this heterogeneity it seems necessary to standardize the utilization modalities of HCIP in peritoneal carcinosis from ovarian background
Interventions
DRUGCisplatin
DRUGBevacizumab
Sponsors
Gustave Roussy, Cancer Campus, Grand Paris
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Stage IIIC unresectable ovarian, tubes or peritoneal primitive adenocarcinoma according to FIGO classification previously treated with 6 cycles of carboplatin-cisplatin neoadjuvant chemotherapy with a response allowing complete surgery after the 6 cycles 2. Time frame between the sixth platin injection and the CRS + HCIP \< 10 weeks 3. No disease progression during the neoadjuvant chemotherapy 4. 18 \</= âge \</= 65 ans 5. Performance Status OMS \< 2 6. Hematological function : PNN \>/= 1.5x10\^9/L, platelets \>/= 150x10\^9/L, hemoglobin \> 9 g /dl (transfusion allowed) 7. Hepatic function : Bilirubin \</= 1,5 x LSN, ASAT (SGOT) and ALAT (SGPT) \</= 3 x LSN, Phosphatases alkaline \</= 3 x LSN 8. No kidney related pathology, plasmatic creatinine \< 140 µmol/l, creatinine clearance \> 60 ml/min (Cockcroft formula) and urinary strip \<2 (If urinary strip \>/= 2, proteinuria \< 1g/24h) 9. Plasmatic albumine \> 25 g/l 10. HIV negative status 11. Affiliation to social security 12. Signed informed consent
Exclusion criteria
1. Incomplete cell kill surgery 2. Non-epithelial ovarian cancer 3. Borderline tumors 4. Non in complete remission previous cancer for more than 5 five years before inclusion 5. Uncontrolled high blood pressure (blood pressure \> 150/100 mm Hg despite antihypertensive treatment) 6. Previous abdominal or pelvic radiotherapy 7. Previous pathology of the central nervous system, except for well controlled pathology like epilepsy 8. Previous stroke, transient ischemic attacks or subarachnoid hemorrhage 9. Previous pulmonary embolism 10. Pregnant or breastfeeding women (Women in age must have a blood negative pregnancy test at least 15 days before going under surgery) 11. Participation to an other clinical trial within 30 days before inclusion in the study 12. Known hypersensitivity to platin or bevacizumab 13. Not healed wound, ulcer or bone fracture 14. Previous haemorrhagic or thrombotic malfunction \< 6 months 15. Significant CArdiovascular disorder including: * Heart attack or unstable angina within the 6 months before inclusion * Grade \> 1 congestive heart failure according to the NYHA classification * Uncontrolled cardiac arrhythmia despite of treatment (patients with atrial fibrillation for which the pace is under control can be include) 16. Long term or recent (within 10 days before inclusion) medication using Aspirin at dosage \> 325 mg/day 17. Long term or recent (within 10 days before inclusion) medication using anticoagulant per os or parenteral or thrombolytic given at full dosage for therapeutic purpose. 18. Grade \> 1 previous sensory and motor neuropathies according to CTC AE V4.0 19. Previous abdominal fistula, GI perforation or intra-abdominal abscess within 6 months before first administration of bevacizumab 20. Proof of any other disease, metabolic malfunction, physical or laboratory exam showing any possibility of disease or condition contraindicating administration of the drug under trial or exsposing the patient to several complications related to the treatment. 21. Persons deprived of liberty 22. Impossibility to comply with the medical following of the treatment for geographical, social or mental reason
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Toxicity | Assessed at week 4 and 8 after HCIP then every 3 weeks up to 15 months | Using NCI CTCV4 |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival | Assessed every 3 weeks from HCIP until progression up to 30 months |
Countries
France
Outcome results
None listed